Welcome to our dedicated page for Onconetix news (Ticker: ONCO), a resource for investors and traders seeking the latest updates and insights on Onconetix stock.
Onconetix, Inc. develops and commercializes biotechnology solutions for men's health and oncology, with Proclarix, an in vitro diagnostic test for prostate cancer approved for sale in the European Union, as a core company-specific product. News about ONCO commonly centers on diagnostic commercialization, clinical or regulatory disclosures, operating and financial results, and material agreements tied to its biotechnology business.
Company updates also cover capital-structure actions, including preferred stock and warrant financings, shareholder votes, reverse stock splits, Nasdaq listing compliance matters, and board or executive governance changes.
Onconetix (Nasdaq: ONCO) reported Q1 2026 progress at subsidiary Proteomedix, developer of the Proclarix® blood test for clinically significant prostate cancer. Two new peer-reviewed publications from Danish studies support Proclarix® in reducing overdiagnosis and unnecessary biopsies and in predicting transition from active surveillance to treatment.
According to Onconetix, PMX also initiated the U.S. multi-center PRIME validation study with Labcorp, targeting up to 500 men, and expanded European use, including a UK screening initiative and a new collaboration partner in Turkey.
Onconetix (Nasdaq: ONCO) is acquiring Realbotix LLC in an all-stock share exchange and highlighted Realbotix's April 8, 2026 delivery of the first Vinci-equipped humanoid robot to Ericsson. Vinci is a patented AI vision system that recognizes returning users, recalls conversations, and tracks engagement for data collection.
The combined company is expected to trade on Nasdaq after closing, anticipated in the second half of 2026, subject to shareholder and regulatory approvals.
Onconetix (Nasdaq: ONCO) disclosed that Realbotix expects to deliver 19 previously ordered humanoid robots and related AI implementations across March, April, and May 2026 as it scales production capacity. Onconetix previously entered a definitive all-stock share exchange to acquire Realbotix LLC, with closing anticipated in 2H 2026, subject to shareholder and regulatory approvals. This update is provided for informational purposes and includes forward-looking statements; investors are cautioned against undue reliance.
Onconetix (Nasdaq: ONCO) announced leadership changes tied to a pending acquisition of Realbotix LLC on March 31, 2026. David White became CEO effective March 18, 2026; Sammy Dorf joined the Board and Audit Committee effective March 19, 2026. Karina Fedasz will remain Interim CFO.
The appointments are presented as strengthening governance and execution as the company advances a previously announced definitive agreement to acquire AI-powered humanoid robot developer Realbotix.
Onconetix (Nasdaq: ONCO) highlighted that Realbotix’s humanoid robot was featured as a live connected endpoint in Ericsson’s pre-standard 6G over-the-air trial at Ericsson’s U.S. headquarters in Plano, Texas on March 25, 2026. The robot streamed video and interacted in real time over Ericsson’s test network, demonstrating AI-agnostic integration across cloud and network environments. Onconetix reiterated its definitive share exchange agreement to acquire 100% of Realbotix LLC in an all-stock transaction announced February 12, 2026; closing and Nasdaq listing are expected in the second half of 2026, subject to shareholder and regulatory approvals.
Onconetix (NASDAQ: ONCO) announced a 1-for-5 reverse stock split effective 12:01 a.m. ET on March 25, 2026.
The Board set the ratio after stockholder approval on February 3, 2026; shares outstanding will fall from ~3.6 million to ~0.7 million to help meet Nasdaq's $1.00 minimum bid requirement.
Onconetix (Nasdaq: ONCO) will acquire Realbotix LLC in an all-stock share exchange that transfers 100% of Realbotix equity to Onconetix. The combined company expects to trade on Nasdaq and the deal is targeted to close in the second half of 2026.
Following closing, Realbotix Parent is expected to own between 75% and 90% of fully diluted common shares; Andrew Kiguel will become CEO of the combined company. Closing remains subject to shareholder and regulatory approvals in the US and Canada.
Realbotix (ONCO) agreed on February 11, 2026 to sell 100% of its subsidiary Realbotix, LLC to NASDAQ-listed Onconetix (NASDAQ: ONCO) in an all-stock deal.
Realbotix will receive a variable 75%–90% stake of ONCO post-close, retain control of Abyss Creations, and can appoint four of five ONCO directors. Closing is expected before end of Q3 2026.
Onconetix (NASDAQ:ONCO), a biotechnology company focused on men's health and oncology, has announced multiple significant financial transactions. The company has secured a $12.9 million private placement through Series D Preferred Stock and Warrants, with $9.3 million paid in cash and the remainder offsetting existing debts.
The financing includes warrants to purchase up to 4,362,827 shares of common stock at an initial exercise price of $3.6896 per share. Additionally, Onconetix has settled its $8.8 million debt with Veru, Inc. through a combination of $6.3 million cash payment and conversion of $2.5 million into Series D Preferred Stock and warrants. The company has also terminated its previously planned merger with Ocuvex, Inc.
Onconetix (NASDAQ:ONCO) and Ocuvex Therapeutics have mutually agreed to terminate their merger agreement originally announced on July 16, 2025. The decision comes after both companies determined that pursuing independent paths would better serve their respective stakeholders.
Despite the merger termination, Ocuvex announced positive developments, including obtaining its New Jersey state pharmaceutical license and the upcoming commercial launch of Omlonti in the coming weeks. Both companies' leadership expressed confidence in their independent growth trajectories and maintained a collaborative spirit throughout the process.